References of "Meunier, Pierre"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEffects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier, Pierre; Roux, C.; Ortolani, S. et al

in Osteoporosis International (2009), 20

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33 ... [more ▼]

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. INTRODUCTION: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. METHODS: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. RESULTS: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction = 0.67, p < 0.001). Among patients with two or more prevalent vertebral fractures, risk reduction was 36% (p < 0.001). QoL, assessed by the QUALIOST(R), was significantly better (p = 0.025), and patients without back pain were greater (p = 0.005) with strontium ranelate than placebo over 4 years. Lumbar BMD increased over 5 years in patients who continued with strontium ranelate, while it decreased in patients who switched to placebo. Emergent adverse events were similar between groups. CONCLUSION: In this 4- and 5-year study, strontium ranelate is an effective and safe treatment for long-term treatment of osteoporosis in postmenopausal women. [less ▲]

Detailed reference viewed: 48 (11 ULg)
Full Text
Peer Reviewed
See detailCorrélation entre l'augmentation de la densité minérale osseuse et la réduction du risque fracturaire lors d'un traitement par ranélate de strontium
Bruyère, Olivier ULg; Cormier, C.; Fardellone, Patrice et al

in Revue du Rhumatisme (2006, December), 73

Detailed reference viewed: 7 (4 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti-fracture efficacy over five years in post menopausal osteoporotic women
Reginster, Jean-Yves ULg; Meunier, Pierre; Roux, Christian et al

in Arthritis and Rheumatism (2006, November), 54(Suppl),

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fractures status
Roux, Christian; Fardellone, P.; Fechtenbaum, Jacques et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 359

Detailed reference viewed: 10 (6 ULg)
Full Text
Peer Reviewed
See detailMeta-analysis of the effects of inhaled corticosteroids on bone in asthmatic and COPD patients
Richy, Florent; Bousquet, Jean; Devogelaer, Jean-Pierre et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 464

Detailed reference viewed: 2 (0 ULg)